NO961536L - Preparation of bisphosphonates and growth hormone secretagogue - Google Patents

Preparation of bisphosphonates and growth hormone secretagogue

Info

Publication number
NO961536L
NO961536L NO961536A NO961536A NO961536L NO 961536 L NO961536 L NO 961536L NO 961536 A NO961536 A NO 961536A NO 961536 A NO961536 A NO 961536A NO 961536 L NO961536 L NO 961536L
Authority
NO
Norway
Prior art keywords
bisphosphonates
growth hormone
preparation
hormone secretagogue
secretagogue
Prior art date
Application number
NO961536A
Other languages
Norwegian (no)
Other versions
NO961536D0 (en
Inventor
Barry J Gertz
Gideon A Rodan
Roy G Smith
Matthew J Wyvratt
Arthur A Patchett
Original Assignee
Merck & Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck & Co Inc filed Critical Merck & Co Inc
Publication of NO961536D0 publication Critical patent/NO961536D0/en
Publication of NO961536L publication Critical patent/NO961536L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Bisfosfonater i kombinasjon med veksthormonsekretagoga reduserer de skadelige effektene av osteoporose hos eldre pasienter.Bisphosphonates in combination with growth hormone secretagogue reduce the deleterious effects of osteoporosis in elderly patients.

NO961536A 1993-10-19 1996-04-18 Preparation of bisphosphonates and growth hormone secretagogue NO961536L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13929693A 1993-10-19 1993-10-19
US25909194A 1994-06-13 1994-06-13
PCT/US1994/011912 WO1995011029A1 (en) 1993-10-19 1994-10-18 Combination of bisphosphonates and growth hormone secretagogues

Publications (2)

Publication Number Publication Date
NO961536D0 NO961536D0 (en) 1996-04-18
NO961536L true NO961536L (en) 1996-06-18

Family

ID=26837073

Family Applications (1)

Application Number Title Priority Date Filing Date
NO961536A NO961536L (en) 1993-10-19 1996-04-18 Preparation of bisphosphonates and growth hormone secretagogue

Country Status (16)

Country Link
EP (1) EP0813414A4 (en)
JP (1) JPH09504525A (en)
KR (1) KR960705575A (en)
CN (1) CN1136278A (en)
AU (1) AU8083694A (en)
BG (1) BG100517A (en)
BR (1) BR9407869A (en)
CA (1) CA2173333A1 (en)
CZ (1) CZ109196A3 (en)
FI (1) FI961681A (en)
HU (1) HUT75224A (en)
LV (1) LV11432B (en)
NO (1) NO961536L (en)
PL (1) PL314003A1 (en)
SK (1) SK49796A3 (en)
WO (1) WO1995011029A1 (en)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5686624A (en) * 1992-01-30 1997-11-11 Sanofi 1-benzenesulfonyl-1,3-dihydro-indol-2-one derivatives, their preparation and pharmaceutical compositions in which they are present
US20020111461A1 (en) 1999-05-21 2002-08-15 Todd C. Somers Low molecular weight peptidomimetic growth hormone secretagogues
US5798337A (en) * 1994-11-16 1998-08-25 Genentech, Inc. Low molecular weight peptidomimetic growth hormone secretagogues
ATE288444T1 (en) * 1995-05-29 2005-02-15 Pfizer DIPEPTIDES THAT STIMULATE THE RELEASE OF GROWTH HORMONES
JPH11513989A (en) * 1995-10-27 1999-11-30 メルク エンド カンパニー インコーポレーテッド Wet granulation of growth hormone secretagogue
US6531314B1 (en) 1996-12-10 2003-03-11 Merck & Co., Inc. Growth hormone secretagogue receptor family
JP3798024B2 (en) 1995-12-13 2006-07-19 メルク エンド カンパニー インコーポレーテッド Growth hormone secretagogue receptor assay
TW432073B (en) 1995-12-28 2001-05-01 Pfizer Pyrazolopyridine compounds
HN1996000101A (en) * 1996-02-28 1997-06-26 Inc Pfizer COMBINED THERAPY FOR OSTEOPOROSIS
JP2000512274A (en) * 1996-05-31 2000-09-19 ノボ ノルディスク アクティ―ゼルスカブ Growth hormone components and bone antiresorptives in the periodic (consistent) treatment of osteoporosis
AU4993497A (en) * 1996-10-25 1998-05-22 Merck & Co., Inc. Convergent process for the preparation of a growth hormone secretagogue
US6376477B2 (en) 1996-11-25 2002-04-23 Merck & Co., Inc. Combination of an agent that binds to the androgen receptor and a bisphosphonic acid in the prevention and/or treatment of diseases involving calcium or phosphate metabolism
GB2324726A (en) * 1997-05-01 1998-11-04 Merck & Co Inc Combination Therapy for the Treatment of Osteoporosis
ZA987385B (en) * 1997-08-19 2000-04-18 Lilly Co Eli Growth hormone secretagogues.
US6211174B1 (en) * 1997-10-31 2001-04-03 Merck & Co., Inc. Naphtho-fused lactams promote release of growth hormone
IT1296495B1 (en) * 1997-11-21 1999-06-25 Prodotti Antibiotici Spa USE OF BISPHOSPHONATES IN THE PREPARATION OF PHARMACEUTICAL FORMS FOR INTRAMUSCULAR ADMINISTRATION
US6682908B1 (en) 1998-07-10 2004-01-27 Merck & Co., Inc. Mouse growth hormone secretagogue receptor
EP1097170A1 (en) 1998-07-13 2001-05-09 Merck & Co., Inc. Growth hormone secretagogue related receptors and nucleic acids
US6645726B1 (en) 1998-08-10 2003-11-11 Merck & Co., Inc. Canine growth hormone secretagogue receptor
EP1112071A4 (en) * 1998-08-18 2003-03-19 Lilly Co Eli Growth hormone secretagogues
US6639076B1 (en) 1998-08-18 2003-10-28 Eli Lilly And Company Growth hormone secretagogues
AR013994A1 (en) * 1998-10-30 2001-01-31 Gador Sa PROCEDURE AND PREPARATIONS THAT SELECTIVELY MODULATE THE FUNCTION OF THE OSTEOBLASTO FOR THE PREVENTION AND TREATMENT OF FRAGILIZING OSTEOPATHIES.
AU1525700A (en) * 1998-11-19 2000-06-05 Board Of Trustees Of The University Of Arkansas, The Increasing bone strength with selected bisphosphonates
US6828331B1 (en) 1999-02-19 2004-12-07 Eli Lilly And Company Growth hormone secretagogues
AU4782600A (en) * 1999-06-02 2000-12-28 Procter & Gamble Company, The Oral preparations of etidronate disodium
EP1159964B1 (en) 2000-05-31 2009-10-28 Pfizer Products Inc. Use of growth hormone secretagogues for stimulating gastrointestinal motility
US6548042B2 (en) 2000-08-07 2003-04-15 Arstad Erik Bis-phosphonate compounds
ES2243457T3 (en) * 2001-01-23 2005-12-01 Gador S.A. COMPOSITION THAT INCLUDES BIFOSPHONATES FOR THE PREVENTION AND / OR TREATMENT OF METABOLIC BONE DISORDERS, PROCEDURE OF PREPARATION OF SUCH COMPOSITION AND USES OF THE SAME.
US7125840B2 (en) 2001-10-09 2006-10-24 Eli Lilly And Company Substituted dipeptides as growth hormone secretagogues
ES2266798T3 (en) 2002-04-09 2007-03-01 Eli Lilly And Company SECRETAGODS OF GROWTH HORMONE.
GB0213715D0 (en) 2002-06-14 2002-07-24 Syngenta Ltd Chemical compounds
CA2524610C (en) * 2003-05-07 2014-03-25 Osteologix A/S Strontium combinations for prophylaxis/treatment of cartilage and/or bone conditions
US7476653B2 (en) 2003-06-18 2009-01-13 Tranzyme Pharma, Inc. Macrocyclic modulators of the ghrelin receptor
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
MX2007002033A (en) 2004-08-19 2007-04-26 Vertex Pharma Modulators of muscarinic receptors.
US7786141B2 (en) 2004-08-19 2010-08-31 Vertex Pharmaceuticals Incorporated Dihydrospiroindene modulators of muscarinic receptors
RU2007124373A (en) 2004-11-29 2009-01-10 Вертекс Фармасьютикалз Инкорпорейтед (Us) MUSCARINE RECEPTION MODULATORS
JP2009521483A (en) 2005-12-22 2009-06-04 バーテックス ファーマシューティカルズ インコーポレイテッド Muscarinic receptor modulators
RU2008137593A (en) 2006-02-22 2010-03-27 Вертекс Фармасьютикалз Инкорпорейтед (Us) MUSCARINE RECEPTOR MODULATORS
AU2007221220A1 (en) 2006-02-22 2007-09-07 Vertex Pharmaceuticals Incorporated Spiro condensed piperidnes as modulators of muscarinic receptors
CU23558A1 (en) 2006-02-28 2010-07-20 Ct Ingenieria Genetica Biotech COMPOUNDS ANALOG TO THE PEPTIDIC SECRETAGOGS OF THE GROWTH HORMONE
EP2040706A2 (en) 2006-06-29 2009-04-01 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
EP2051712A2 (en) 2006-08-15 2009-04-29 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
JP2010501561A (en) 2006-08-18 2010-01-21 バーテックス ファーマシューティカルズ インコーポレイテッド Modulator of muscarinic receptor
AU2008241532A1 (en) 2007-02-09 2008-10-30 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor modulators and methods of using the same
EP2155769B1 (en) 2007-05-04 2012-06-27 Katholieke Universiteit Leuven KU Leuven Research & Development Tissue degeneration protection
EP2207549A1 (en) 2007-10-03 2010-07-21 Vertex Pharmceuticals Incorporated Modulators of muscarinic receptors
WO2013190520A2 (en) 2012-06-22 2013-12-27 The General Hospital Corporation Gh-releasing agents in the treatment of vascular stenosis and associated conditions
SG11201609050UA (en) 2014-05-30 2016-12-29 Pfizer Carbonitrile derivatives as selective androgen receptor modulators
JP2021526792A (en) 2018-06-06 2021-10-11 マサチューセッツ インスティテュート オブ テクノロジー Circular RNA for translation in eukaryotic cells
EP3972653A1 (en) 2019-05-22 2022-03-30 Massachusetts Institute of Technology Circular rna compositions and methods
EP3920976B1 (en) 2019-12-04 2023-07-19 Orna Therapeutics, Inc. Circular rna compositions and methods
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU569391B2 (en) * 1984-04-30 1988-01-28 Procter & Gamble Company, The Treating osteoporosis
DE3514583A1 (en) * 1984-04-30 1985-10-31 The Procter & Gamble Co., Cincinnati, Ohio Use of a two-phase or multiphase composition for the treatment or prevention of osteoporosis
NZ258412A (en) * 1992-12-11 1997-01-29 Merck & Co Inc Spiro-fused piperidine derivatives and pharmaceutical compositions
US5284841A (en) * 1993-02-04 1994-02-08 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5434261A (en) * 1993-07-26 1995-07-18 Merck & Co., Inc. Benzo-fused lactams promote release of growth hormone
US5545735A (en) * 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone

Also Published As

Publication number Publication date
EP0813414A1 (en) 1997-12-29
CA2173333A1 (en) 1995-04-27
CZ109196A3 (en) 1996-10-16
CN1136278A (en) 1996-11-20
EP0813414A4 (en) 1999-07-21
BR9407869A (en) 1996-10-29
HUT75224A (en) 1997-04-28
AU8083694A (en) 1995-05-08
WO1995011029A1 (en) 1995-04-27
SK49796A3 (en) 1997-05-07
BG100517A (en) 1996-11-29
LV11432B (en) 1996-12-20
PL314003A1 (en) 1996-08-05
JPH09504525A (en) 1997-05-06
HU9601013D0 (en) 1996-06-28
FI961681A (en) 1996-06-12
FI961681A0 (en) 1996-04-17
KR960705575A (en) 1996-11-08
LV11432A (en) 1996-08-20
NO961536D0 (en) 1996-04-18

Similar Documents

Publication Publication Date Title
NO961536L (en) Preparation of bisphosphonates and growth hormone secretagogue
AU3022692A (en) Methods for the treatment of osteoporosis using bone-active phosphonates and parathyroid hormone
AU8904491A (en) Foot and leg splint device
DE69527672D1 (en) Brace for correcting the foot and footwear with this brace
IT8819961A0 (en) MODULAR COMPOSITE PROSTHETIC DEVICE FOR LEG AND FOOT.
AU6094096A (en) Use of gamma-hydroxybutyrate for the stimulation of sleep-re lated growth hormone secretion
DE69217736T2 (en) Inhibited acryloxy and methacryloxysilanes
GB9806632D0 (en) Peptide factor
DE69418504T2 (en) Double fixation prosthesis
DK487587A (en) FLUORED AND CALCIUM AGENTS WITH DELAYED DELIVERY
IL101587A0 (en) Biologically active peptide composition and uses therefor
ZA936692B (en) Physiologically active peptide composition
AU9052991A (en) Use of angiotensin ii antagonist in the treatment of infarction
MX9805506A (en) Novel medical use of an ace-inhibitor for treatment of dyspeptic symptoms.
AU9084191A (en) Use of angiotensin ii receptor antagonists in the treatment of hemorragic stroke
ZA941199B (en) Physiologically active compound HS-1 and process for the preparation of the same
NO167146C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE CONDENSED DIAZEPINONES.
NO168477C (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE CONDENSED DIAZEPINONES.
NO960545D0 (en) Treatment of adverse effects associated with the administration of extracellular hemoglobin
NO921086L (en) PROCEDURE FOR THE PREPARATION AND USE OF SUBSTITUTED 2 ', 3'-DIDESOXY-5-TRIFLUORMYTYLURIDINES
NO903939L (en) ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE CONDENSED DIAZEPINONES.
ES2094930T3 (en) NEW TROMBINE INHIBITING PROTEIN ISOLATED FROM TICKS.
IL86156A0 (en) Preparation of l-phenylalanine with the aid of recombinant bacteria
AU607118B3 (en) Foot leg and hip exerciser
IL107773A0 (en) Human pituitary cells lines methods for the preparation thereof and uses therefor